Key Points
- CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health on April 22 at an average price of $54.29 for $382,201.60, reducing his stake by 6.4% to 102,920 shares valued at about $5.59 million; the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
- He has repeatedly sold shares across multiple transactions since February (including several 7,040-share lots and larger sales), totaling roughly $4.1 million, indicating a sustained pattern of insider selling.
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $54.29, for a total transaction of $382,201.60. Following the transaction, the chief executive officer owned 102,920 shares in the company, valued at $5,587,526.80. The trade was a 6.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jack Bendheim also recently made the following trade(s):
- On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $54.64, for a total transaction of $384,665.60.
- On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20.
- On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
- On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
- On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total transaction of $272,764.80.
- On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total transaction of $258,244.80.
- On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
- On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
- On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total value of $361,996.80.
- On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
Phibro Animal Health Trading Up 1.3%
NASDAQ PAHC opened at $54.69 on Friday. The firm has a market cap of $2.22 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 0.83 and a beta of 0.69. Phibro Animal Health Corporation has a 1-year low of $17.18 and a 1-year high of $60.08. The stock has a 50-day moving average of $53.63 and a 200-day moving average of $45.50. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, sell-side analysts forecast that Phibro Animal Health Corporation will post 3.03 EPS for the current year.
Phibro Animal Health Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were issued a $0.12 dividend. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health's dividend payout ratio (DPR) is currently 21.33%.
Institutional Trading of Phibro Animal Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Inspire Investing LLC bought a new stake in Phibro Animal Health in the first quarter valued at $158,000. Pictet Asset Management Holding SA bought a new position in Phibro Animal Health in the 1st quarter worth $258,000. Louisiana State Employees Retirement System purchased a new stake in shares of Phibro Animal Health in the 1st quarter worth about $503,000. Balboa Wealth Partners lifted its position in shares of Phibro Animal Health by 30.3% in the 1st quarter. Balboa Wealth Partners now owns 7,879 shares of the company's stock worth $436,000 after purchasing an additional 1,833 shares during the period. Finally, Caitlin John LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter valued at about $266,000. Hedge funds and other institutional investors own 99.34% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently commented on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Citigroup began coverage on shares of Phibro Animal Health in a report on Wednesday, April 15th. They issued a "neutral" rating and a $62.00 price target on the stock. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of "Hold" and a consensus price target of $42.40.
Check Out Our Latest Research Report on PAHC
Phibro Animal Health Company Profile
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
